Search | IOVS | ARVO Journals

View

Showing 1 – 2 of 2

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2017

Twelve-Month Outcomes of Aflibercept vs. Ranibizumab for Wet Macular Degeneration

Hussein Almuhtaseb; Luke Michaels; Thanos Vardarinos; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):431. doi:

ARVO Annual Meeting Abstract June 2017

Twenty Four-Month Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration: Different Treatment Regimens in Year Two based on the Macular Status at the End of Year One

Luke Michaels; Hussein Almuhtaseb; Adham Youssef; Christina A Rennie; Andrew J Lotery

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):433. doi:

Advertisement